Advanced Inhalation Therapies (AIT), which is developing inhaled nitric oxide drug-device therapies for respiratory infections, filed on Tuesday with the SEC to raise up to $36 million in an initial public offering.
The Rehovot, Israel-based company, which...read more
Five companies had below-average returns and brought the number 2015 IPOs up to 22, a 39% decline from this time last year...IPO highlights during the week of February 9, 2015
...read more
Bellerophon Therapeutics, which is developing drug-device therapies for pulmonary and cardiac diseases, raised $60 million by offering 5 million shares at $12, below the range of $14 to $16. The company had originally planned to sell 4 million shares....read more
Twelve deals are on the calendar to raise $1.2 billion, which would make it the year's biggest week for IPOs by proceeds and count. However, those numbers could decline...read more
Breathe easy: Advanced Inhalation Therapies files for a $36 million IPO
Advanced Inhalation Therapies (AIT), which is developing inhaled nitric oxide drug-device therapies for respiratory infections, filed on Tuesday with the SEC to raise up to $36 million in an initial public offering. The Rehovot, Israel-based company, which...read more
US IPO Weekly Recap: Big data produces small returns in a selective IPO market
Five companies had below-average returns and brought the number 2015 IPOs up to 22, a 39% decline from this time last year... IPO highlights during the week of February 9, 2015 ...read more
Bellerophon Therapeutics prices IPO at $12.00, below the range
Bellerophon Therapeutics, which is developing drug-device therapies for pulmonary and cardiac diseases, raised $60 million by offering 5 million shares at $12, below the range of $14 to $16. The company had originally planned to sell 4 million shares....read more
Week ahead: 12 IPOs feature health care, holdovers and a $500 million health tech IPO
Twelve deals are on the calendar to raise $1.2 billion, which would make it the year's biggest week for IPOs by proceeds and count. However, those numbers could decline...read more